Epinephrine Autoinjector Shortage Predicted After Recall

An estimated half a million epinephrine autoinjectors are coming off the market. The US Food and Drug Administration (FDA) is advising patients to call their doctor for an alternative, but some say there won't be enough supply to meet the demand.

"We're going to run out of autoinjectors in certain places. It's going to be a problem," said Bryan Martin, DO, president-elect of the American College of Allergy, Asthma & Immunology (ACAAI).

Sanofi US voluntarily recalled its epinephrine injection (Auvi-Q) from the market because patients taking it for anaphylaxis could receive an inaccurate and inadequate dose, as reported by Medscape Medical News.

As of October 26, the company had received 26 unconfirmed reports of suspected device malfunction from patients in the United States and Canada. No one died as a result, but patients continued to experience symptoms of underlying hypersensitivity reaction, according to an FDA news release.

Auvi-Q is distributed in packs that contain two active injectors and a training injector. There are roughly 490,000 packs of Auvi-Q on the market, and all are subject to the recall.

We're going to run out of autoinjectors in certain places. It's going to be a problem.

That means a lot of phone calls, a lot of questions, and a lot of stress. "It will be very crazy," Dr Martin told Medscape Medical News.

This will be among the hot topics at the upcoming ACAAI 2015 Scientific Meeting.

The plenary on helping physicians cope with the stresses they face seems to be aptly titled: The Sky is Not Falling.

The plenary will address regulatory changes, new payment models, the factors driving them, and a psychologic perspective on the use of tools, such as resilience and mindfulness, to manage them, Dr Martin said.


Could I Be Allergic? Discover Your Allergy Triggers See Slideshow

Epinephrine Autoinjector Shortage Predicted After Recall. Medscape. Nov 03, 2015.

Health Solutions From Our Sponsors